J
Josy Reiffers
Researcher at Centre national de la recherche scientifique
Publications - 301
Citations - 16342
Josy Reiffers is an academic researcher from Centre national de la recherche scientifique. The author has contributed to research in topics: Transplantation & Leukemia. The author has an hindex of 60, co-authored 301 publications receiving 15784 citations. Previous affiliations of Josy Reiffers include Hammersmith Hospital & University of Poitiers.
Papers
More filters
Journal ArticleDOI
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon,Delphine Rea,Joelle Guilhot,François Guilhot,Françoise Huguet,Franck E. Nicolini,Laurence Legros,Aude Charbonnier,Agnès Guerci,Bruno Varet,Gabriel Etienne,Josy Reiffers,Philippe Rousselot +12 more
TL;DR: Imatinib discontinuation in this setting yields promising results for molecular relapse-free survival, raising the possibility that, at least in some patients, CML might be cured with tyrosine kinase inhibitors.
Journal ArticleDOI
Noninvasive Ventilation in Immunosuppressed Patients with Pulmonary Infiltrates, Fever, and Acute Respiratory Failure
Gilles Hilbert,Didier Gruson,Frédéric Vargas,Ruddy Valentino,G Gbikpi-Benissan,Michel Dupon,Josy Reiffers,J. P. Cardinaud +7 more
TL;DR: In selected immunosuppressed patients with pneumonitis and acute respiratory failure, early initiation of noninvasive ventilation is associated with significant reductions in the rates of endotracheal intubation and serious complications and an improved likelihood of survival to hospital discharge.
Journal ArticleDOI
Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance
François Xavier Mahon,Michael W. Deininger,Beate Schultheis,Jerome Chabrol,Josy Reiffers,John M. Goldman,Junia V. Melo +6 more
TL;DR: It is concluded that BCR-ABL-positive cells can evade the inhibitory effect of STI571 by different mechanisms, such as Bcr-Abl overexpression, reduced intake mediated by Pgp, and, possibly, acquisition of compensatory mutations in genes other than BCR -ABL.
Journal ArticleDOI
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia
Picard Stephane,Karine Titier,Gabriel Etienne,Emmanuelle Teilhet,Dominique Ducint,M.-A. Bernard,Régis Lassalle,Gerald Marit,Josy Reiffers,Bernard Bégaud,Nicholas Moore,Mathieu Molimard,Francois-Xavier Mahon +12 more
TL;DR: Monitoring of imatinib plasma levels could be very useful for the management of patients with CML or should at least be checked in the case of treatment failure or suboptimal response.
Journal ArticleDOI
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years
Philippe Rousselot,Françoise Huguet,Delphine Rea,Laurence Legros,Jean Michel Cayuela,Odile Maarek,Odile Blanchet,Gerald Marit,Eliane Gluckman,Josy Reiffers,Martine Gardembas,Francois-Xavier Mahon +11 more
TL;DR: It is hypothesized that relapses observed within 6 months reflect the kinetics of undetectable dividing chronic myelogenous leukemia (CML) cells, which may be eradicated or controlled in long-term nonrelapsing patients, as described in the study.